Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Creative Medical Technology Holdings, Inc. - Common Stock
(NQ:
CELZ
)
3.161
-0.109 (-3.35%)
Streaming Delayed Price
Updated: 3:34 PM EDT, Oct 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Creative Medical Technology Holdings, Inc. - Common Stock
Creative Medical Technology Holdings Provides Corporate Update
March 27, 2024
From
Creative Medical Technology Holdings, Inc.
Via
Business Wire
Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA
March 08, 2024
Via
AB Newswire
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
March 07, 2024
From
Creative Medical Technology Holdings, Inc.
Via
Business Wire
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
March 06, 2024
From
Creative Medical Technology Holdings, Inc.
Via
Business Wire
What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
August 24, 2023
Via
ACCESSWIRE
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
December 20, 2023
Via
ACCESSWIRE
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update
July 13, 2023
Via
ACCESSWIRE
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
March 07, 2023
From
Creative Medical Technology Holdings, Inc.
Via
Business Wire
Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects
February 14, 2023
From
Creative Medical Technology Holdings, Inc.
Via
Business Wire
InvestorNewsBreaks – Creative Medical Technology (NASDAQ: CELZ) Expects $17 Million Gross Proceeds from Private Placement
May 16, 2022
Via
Investor Brand Network
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
March 24, 2022
Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor...
Via
FinancialNewsMedia
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today